Cost effectiveness of peer support for type 2 diabetes

International Journal of Technology Assessment in Health Care

Volumn 28, Issue 1, 2012, Pages 3-11

  Gillespie, Paddy ^a   O'Shea, Eamon ^a   Paul, Gillian ^b   O'Dowd, Tom ^b   Smith, Susan M ^c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Cost effectiveness analysis; General practice; Peer support; Type 2 diabetes

Indexed keywords

CONFIDENCE INTERVAL; CONTROL STRATEGIES; COST EFFECTIVENESS ANALYSIS; DIABETES CARE; FINAL COSTS; GENERAL PRACTICE; GROUP-BASED; HEALTH CARE COSTS; INCREMENTAL COST; IRELAND; LIFETIME COSTS; PEER SUPPORT; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIAL; RISK FACTORS; TOTAL COSTS; TYPE-2 DIABETES; UNITED KINGDOM; WILLINGNESS TO PAY;

COST EFFECTIVENESS; COSTS; PATIENT TREATMENT; QUALITY CONTROL;

COST BENEFIT ANALYSIS;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PEER GROUP; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PEER GROUP; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RISK REDUCTION BEHAVIOR; SOCIAL SUPPORT; STATISTICS AS TOPIC;

EID: 84859035612     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462311000663     Document Type: Article

References (21)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:569-615.
2. Barry M, Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev Pharmacoecon Outcomes Res. 2009;7:605-611.
3. Briggs A. A Bayesian approach to stochastic cost effectiveness analysis: An illustration and application to blood pressure control in type 2 diabetes. Int J Technol Assess Health Care. 2001;17:69-82. (Pubitemid 32381742)
4. Campbell MK, Elbourne DR, Altman DG, et al. CONSORT statement: Extension to cluster randomised trials. BMJ. 2004;328:702-708. (Pubitemid 38393415)
5. Caro JF, Fisher EB. A solution might be within people with diabetes themselves. Fam Pract. 2010;27(Suppl 1):i1-i2.
6. Brownson CA, Hoerger TJ, Fisher EB, Kilpatrick KE. Cost-effectiveness of diabetes self-management programs in community primary care settings. Diabetes Educ. 2009;35:761-769.
7. Central Bank of Ireland. Dublin. www.centralbank.ie (accessed January 11, 2010).
8. Central Statistics Office. Dublin. www.cso.ie (accessed January 11, 2010).
9. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48:868-877. (Pubitemid 40767979)
10. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747-1759. (Pubitemid 40022410)
11. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: Results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med. 2003;20:442-450. (Pubitemid 36776003)
12. Drummond MF, Sculpher MJ, Torrance GW, O'Brien J, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
13. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2007.
14. Hardin JW, Hilbe JM. Generalised estimating equations. London: Chapman and Hall/CRC Press; 2003.
15. JohnstonK,GrayA,MoherM,Yudkin P,Wright L, Mant D. Reporting the cost-effectiveness of interventions with nonsignificant effect differences: Example from the a trial of secondary prevention of heart disease. Int J Technol Assess Health Care. 2003;19:476-489. (Pubitemid 38649116)
16. Massi-Benedetti M, The cost of diabetes type II in Europe: The CODE-2 study. Diabetologia. 2002;45:S1-S4. (Pubitemid 34762207)
17. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: A report on the fourth Mount Hood Challenge Meeting. Diabetes Care. 2007;30:1638-1646: reprint/30/6/1638 (accessed October 7, 2009).
18. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; Apr 2004. www.nice.org.uk/ page.aspx?o=201974 (reference 0515).
19. Nolan JJ, O'Halloran D, McKenna TJ, Firth R, Redmond S. The cost of treating type 2 diabetes (CODEIRE). Ir Med J. 2006;99:307-310.
20. Paul G, Smith SM, Whitford D, O'Shea E, O'Kelly F, O'Dowd T. Peer support in type 2 diabetes: A randomised controlled trial in primary care with parallel economic and qualitative analyses: Pilot study and protocol. BMC Fam Pract. 2007;8:45.
21. Smith SM, Paul G, Kelly A, Whitford DL, O'Shea E, O'Dowd T. Peer support for type 2 diabetes: A cluster randomized controlled trial. BMJ. 2011;342:d715.